BioSpace News Archive

Gilead Sciences Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine.

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the pricing of its underwritten public follow-on offering (the “Follow-on Offering”) of 1,500,000 ordinary shares at a public offering price of US$15.00 per ordinary share (the “Offering Price”), for gross proceeds of $22,500,000.